Adicet Bio Long Term Debt

Adicet Bio (ACET) currently reports a long-term debt of $22M as of March 2026. That compares with $13M in the prior-year period — up 66.2% year over year. Use the charts on this page to explore Adicet Bio's long-term debt history and peer comparisons.

Adicet Bio's long-term debt increased from $13M to $22M — a 66.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adicet Bio reported $22M in long-term debt as of March 2026. That compares with $13M in the prior-year period — up 66.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $22M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adicet Bio, and consider following ACET for alerts when major investors trade the stock.

Adicet Bio is classified in the Healthcare sector. On long-term debt, it currently shows $22M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACET with unrelated industries.